Unknown

Dataset Information

0

Pseudotyped ?v?6 integrin-targeted adenovirus vectors for ovarian cancer therapies.


ABSTRACT: Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapies. Human adenovirus type 5 (HAdV-C5/Ad5) is a common vector for its ease of manipulation, high production titers and capacity to transduce multiple cell types. However, effective clinical applications are hindered by poor tumor-selectivity and vector neutralization. We generated Ad5/kn48 by pseudotyping Ad5 with the fiber knob domain from the less seroprevalent HAdV-D48 (Ad48). The vector was shown to utilize coxsackie and adenovirus receptor (CAR) but not CD46 for cell entry. A 20-amino acid peptide NAVPNLRGDLQVLAQKVART (A20) was inserted into the Ad5. Luc HI loop (Ad5.HI.A20) and Ad5/kn48 DG loop (Ad5/kn48.DG.A20) to target a prognostic cancer cell marker, ?v?6 integrin. Relative to the Ad5.Luc parent vector, Ad5.HI.A20, Ad5.KO1.HI.A20 (KO1, ablated CAR-binding) and Ad5/kn48.DG.A20 showed ~ 160-, 270- and 180-fold increased transduction in BT-20 breast carcinoma cells (?v?6high). Primary human epithelial ovarian cancer (EOC) cultures derived from clinical ascites provided a useful ex vivo model for intraperitoneal virotherapy. Ad5.HI.A20, Ad5.KO1.HI.A20 and Ad5/kn48.DG.A20 transduction was ~ 70-, 60- and 16-fold increased relative to Ad5.Luc in EOC cells (?v?6high), respectively. A20 vectors transduced EOC cells at up to ~ 950-fold higher efficiency in the presence of neutralizing ovarian ascites, as compared to Ad5.Luc. Efficient transduction and enhanced cancer-selectivity via a non-native ?v?6-mediated route was demonstrated, even in the presence of pre-existing anti-Ad5 immunity. Consequently, ?v?6-targeted Ad vectors may represent a promising platform for local intraperitoneal treatment of ovarian cancer metastases.

SUBMITTER: Uusi-Kerttula H 

PROVIDER: S-EPMC5053699 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

Uusi-Kerttula Hanni H   Davies James J   Coughlan Lynda L   Hulin-Curtis Sarah S   Jones Rachel R   Hanna Louise L   Chester John D JD   Parker Alan L AL  

Oncotarget 20160501 19


Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapies. Human adenovirus type 5 (HAdV-C5/Ad5) is a common vector for its ease of manipulation, high production titers and capacity to transduce multiple cell types. However, effective clinical applications are hindered by poor tumor-selectivity and vector neutralization. We generated Ad5/kn48 by pseudotyping Ad5 with the fiber knob domain from the less seroprevalent HAdV-D48 (Ad48). The vector was show  ...[more]

Similar Datasets

| S-EPMC10363566 | biostudies-literature
| S-EPMC8971729 | biostudies-literature
| S-EPMC6045477 | biostudies-literature
| S-EPMC3566823 | biostudies-literature
| S-EPMC6081240 | biostudies-literature
| S-EPMC4335196 | biostudies-literature
| S-EPMC7855651 | biostudies-literature
| S-EPMC3130354 | biostudies-literature
| S-EPMC7053198 | biostudies-literature
| S-EPMC6213631 | biostudies-literature